focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Preliminary Results

9 Sep 2008 07:00

RNS Number : 9963C
ABCAM Plc
09 September 2008
 
For immediate release 9 September 2008
 
 
ABCAM PLC
("Abcam" or "the Company")
Preliminary results for the year ended 30 June 2008
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is pleased to announce its preliminary results for the year ended 30 June 2008.
 
HIGHLIGHTS
·; Sales increased 49.7% to £36.7m (2007: £24.5m)
·; Pre-tax profits increased 48.2% to £8.2m pre potential offer related costs of £250k
·; Product range grew 29.8% to 44,000 antibodies and related products (2007: 33,900) 
·; Transfer of all polyclonal production to high-throughput- production (HTP) facility successfully completed, further development of monoclonal production programme and significant increase in levels of product characterisation undertaken in-house
·; US subsidiary continued to trade well, and our Japanese subsidiary grew sales by 67.4% in the second half of the year
·; Net cash and short term investments at 30 June 2008 of £14.5m (2007: £10.7m)
·; EPS increased by 43.8% to 16.88p per share (2007: 11.74p)
·; Final dividend increased by 42.9% to 4.56p per share (2007: 3.19p) making a total dividend for the year of 5.60p (2007: 3.99p)
 
David Cleevely, Chairman of Abcam, said: “The year to June 2008 was another year of impressive growth at Abcam, reflected in our strong sales, profits and cash generation, and in the 42.9% increase in our total dividend. The growing international demand for research antibodies, combined with the strength of our brand, product range and strategy, means that the Board looks forward to the future with confidence.”
 
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
www.abcam.com 
 
Numis Securities + 44 (0) 20 7260 1000
Nominated Adviser Michael Meade / Nick Westlake
Corporate Broking James Black
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Mary-Jane Johnson / Susanna Gale 
 
Notes for editors
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA and Tokyo, Japan. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company’s website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world’s largest online resource of high quality and commercially viable antibodies. Abcam now has an online catalogue of over 44,000 products, most of which are antibodies, from over 250 suppliers and employs 184 staff in its three operating companies.
About antibodies
Antibodies are proteins produced by white blood cells in response to the introduction of a foreign body known as an antigen. Antibodies, which have a wide variety of uses in research, diagnostics and therapeutics, are used by bioscientists in research into disease and into the human genome, where they are used to mark and identify specific cells and other living matter. The number of human antibodies of use in research is potentially greater than one million.

 

 
Chairman’s Review
Abcam has recently celebrated its tenth anniversary and I am delighted to report on another outstanding year as the Group continues to go from strength to strength. Demand for research antibodies has never been higher, nor has our reputation. Our highly developed e-commerce platform, offering targeted information and easy access to products, has become the destination of choice for increasing numbers of researchers across the world.
Our intention is to consistently deliver robust growth whilst at the same time investing in the future of the business, thus ensuring that we have a solid and sustainable foundation for long-term development. This has been achieved this year and the business is well set for continued success.
We have achieved strong growth in all the regions in which we operate: sales in the year increased by 49.7% to £36.7m (49.1% on a constant currency basis), whilst gross margins increased from 59.1% to 60.8%. This outstanding performance is a testimony to the quality of the products and support we offer, the scalability of our operation and Abcam’s growing reputation as a quality supplier to the world scientific community.
A key driver of our success is our wealth of product data. This set of data is a tremendous asset and includes technical information, application specific information, user-generated reviews and how our products have been used in published experiments. Using this relevant, easily accessible information, research scientists can identify and purchase the products best suited for their requirements. During the year, our catalogue increased by more than 10,000 products, from 33,900 at the end of the last financial year to over 44,000 at the end of June 2008. Sales of individual products tend to increase the longer they are listed and as more data is gathered. New products contributed £3.2m to sales in the year and we expect sales from these new launches to increase in future years.
Our investments in the year included the continued development of the high-throughput production (HTP) facility. The HTP facility has taken on the production of new and existing polyclonal antibodies and been very successful in adding characterisation data, which is an important driver of growth, to our existing catalogue. A priority for this year has been increasing production efficiencies and managing costs. We have also continued development work on our automated monoclonal development programme. The initial level of sales of the monoclonal antibodies added to the catalogue during the year has been well ahead of expectations and we will continue to prudently manage monoclonal production levels in line with the development of our production process.
Our offices in the USA and Japan have both grown significantly in the year and our commitment to optimising the user experience has driven further investment in our website infrastructure, and the establishment of a dedicated e-commerce team. We are also continuing to build our distributor network in order to improve our geographic reach in parts of the world where an e-commerce model has yet to be fully embraced.
We have continued to attract staff of the highest calibre to ensure that our growth is targeted and well managed. A high proportion of our staff have PhDs and we aim to blend a depth of technical knowledge with strong commercial acumen. In November 2007 we appointed Jeff Iliffe as Chief Financial Officer and, with the extremely valuable contributions from the non-executive directors, we have a strong and effective Board.
Our aim is to continue delivering value to both our customers and our shareholders and I would like to thank them for their continued support. I would also like to extend thanks to our growing number of suppliers and finally to our dedicated and talented staff, who make these achievements possible.
Dividends
The Board’s policy is to distribute 33% of profit after tax as dividends. This was increased from 25% last year, in line with the strong cashflow and growing success of the Group. An interim dividend of 1.04p per share was paid in April 2008 and the Directors are therefore recommending a final dividend of 4.56p per share, making a total for the year of 5.60p. Subject to shareholder approval at the Annual General Meeting in November, this dividend will be paid on 28 November 2008 to shareholders on the register on 7 November 2008.
Outlook
Our track record demonstrates the strength of the combination of our highly developed e-commerce platform, wealth of product data, extensive range of antibodies and high-calibre staff. We have built an attractive position in an exciting market and the Board looks to the future with confidence.
David Cleevely FREng
Chairman
8 September 2008

 

CEO’s Review
We have built a truly international reputation in the research community for the reliability of our products and the support we offer. The development of our systems and the power of the internet enable us to focus our marketing effectively and to provide a targeted, high-value service at the individual researcher level. At the same time, our product range has expanded to more than 44,000 products and sales have increased by 49.7% to £36.7m.
We continue to strike a balance between current year growth and investment for the future. Even so, profit before taxation increased by 48.2% from £5.5m to £8.2m before charging £250k in costs associated with the potential offer process last summer.
What is also very exciting is the 29.8% growth achieved in the number of products in the catalogue and the breadth covered by the new products. One of the strengths of the team that sources externally manufactured antibodies from original equipment manufacturers (OEMs) is the diversity of deals that they can cover in building the catalogue. This year, deals range from one adding almost 3,000 antibodies immediately to those on individual products from niche researchers. It is encouraging also that we have built a sufficient market share such that the desirability of pursuing exclusive product line acquisition (PLA) deals has reduced. We do not rule out doing more PLA deals in the future, if the deals are lucrative; however as a source of growth and capturing market share their role and importance has diminished. Overall, we are now managing relationships with more than 250 suppliers and see growth both from new products that our established suppliers bring to us and from the continued addition of new suppliers. We are also expanding the breadth of antibody-related reagents that we can cover, giving us access to new markets; for example, this year we have almost doubled our proteins range.
Our HTP facility is now well established in its new building. The production levels of polyclonal antibodies now exceed the levels achieved in our old facility, with the capacity to increase this in line with market demand. We are also seeing the monoclonal antibodies coming out of the developmental stages of the facility, and showing good initial sales.
A further, particularly satisfying achievement is the introduction of high-throughput screening assays into the HTP facility, leading to increased levels and quality of characterisation which we can now provide with all our products. This is a key driver of our growth and we are delighted with the amount of characterisation data that is being generated.
Both our OEM product sourcing strategies and HTP product development are driven by our approach to the segmentation of the research market into Core Focus Areas (CFAs). This year we have continued to build our CFA strategy through the development and integration of product, marketing, events and support teams within each CFA. We have found that the CFA approach is very effective in capturing market share and continue to add further CFAs in order to maintain this momentum. We started the year with six CFAs and we added two further to take our total number to eight fully established CFAs.. 
A key area of development based around the CFAs is in the activities of the scientific events team, which organises and runs conferences and seminars. To help across all our CFAs we have also been developing an expert system – the Target Selection Database (TSDB) – to help in the quality of candidate targets that we can select. The TSDB is a powerful data-mining tool that integrates both internal and external scientific data sources to provide a comprehensive profile of the commercial potential of a target in half the time taken previously.
We have a highly efficient business, with end-to-end systems linking the public website directly through to product ordering, inventory management, logistics and accounting. The resulting real-time data gives us strong operational and financial control and enables us to adopt an agile and responsive approach to the management of the business.
Since the creation of the company ten years ago our strong focus has been on serving the researcher and our business philosophy and processes are all based around their needs and the achievement of their objectives. During that time our products have been used in ground-breaking research and referenced in thousands of publications, thus enhancing our international reputation. This commitment is also core to our future as through the development of our systems we build on our relationships, offering an ever more relevant service to each individual as our product range and geographic reach expand.
Jonathan Milner
CEO
8 September 2008

 

Managing Director’s Review
Our new HTP manufacturing facility in Cambridge UK has been open for just over a year and the move from our existing facility has gone well. The production processes for polyclonal antibodies are now established and the development programme for our own monoclonal manufacturing is well underway. During the year we have been commissioning the major pieces of automation equipment from Beckman Coulter needed for scaled-up production of monoclonals. The last of these – the freeze-down workstation for long-term storage of the clones – is scheduled to be commissioned before the end of this calendar year.
This year has marked an important transition for our Tokyo office, which since 1 January 2008 has moved from transacting the majority of our business through our original distributor, to dealing directly with our major sub-dealers in the Japanese market. This enables us both to provide better support to our customers by shortening the communication chain to them and to improve the margin we can realise from selling our products. This transition was always part of the strategy for developing the Tokyo office but I am delighted to report that we have achieved this whilst still delivering 67.4% growth in sales from ¥159.8m (£0.7m) to ¥267.5m (£1.3m), comparing the second half of this financial year with the same period last year.
This year has also seen us continuing our strategy of developing our European sales through our ‘virtual offices’ based out of our Cambridge UK office, enabling European customers to contact us directly in their own language. The results have been very pleasing, particularly in Germany and France. A combination of targeted marketing campaigns and amendments to our discount structure in Europe has meant we have increased sales by 65.5% from €8.9m to €14.7m. As well as contributing to our overall sales, the strength in growth of our European sales has contributed to the margin improvements we have seen this year.
Our North American sales based out of our office in Cambridge MA have also continued to grow from $24.7m to $33.8m, an increase of 36.9%. We have been fortunate to be able to take on an additional 4,500 square feet of adjoining space that has become vacant at our One Kendall Square address. This will enable us to implement smoothly the planned expansion of our operations in North America without the inconvenience of relocating and should provide sufficient space to accommodate up to three years of projected growth.
An area which is fast maturing into an important cornerstone of our business is our scientific events team. We organise and run conferences and seminars in our CFAs , both as part of our core marketing strategy and to build brand awareness and keep us in touch with our customers and the scientific community. We have gradually built up our capability and reputation in the biological events arena, from running two major events in 2006–07 (around Chromatin and Stem Cells) to four in 2007–08. In addition, we have run twenty smaller, one-day events and seminars this year and will expand these further in 2008-09.
Our strong performance this year is again a tribute to the enthusiasm and commitment of our staff. We aim to provide a rewarding and progressive environment for our employees and we are always seeking ways to improve our overall benefits package for all our staff. For example, this year in the UK, despite still being a relatively small company, we are offering a class-leading self-service flexible benefits system where staff can choose from a variety of benefits, ranging from health care and pensions to cycle-to-work schemes, and take best advantage of the tax concessions available via salary sacrifice. We believe that continuing to develop the creative and innovative individuals who have grown up through a young entrepreneurial culture will enable us to grow successfully over the coming years. This is achieved by being open to both interdepartmental transfers and the career aspirations of staff, together with active training and development programmes utilising local initiatives and other opportunities open to staff.
Jim Warwick
Managing Director
8 September 2008

 

FINANCIAL REVIEW
Sales
Sales increased in the year by 49.7% to £36.7m or 49.1% on a constant currency basis i.e. if foreign currency exchange rates had remained unchanged from 2007. (Average exchange rate applied to sales: 2008 £1:$1.997: €1.374: ¥220.051; 2007 £1:$1.925: €1.481: ¥229.699.)
Gross margin
Gross margins reported for the period under review are 60.8% compared with 59.1% for the previous year. The increase of 1.7% is attributable to improved pricing which more than compensated for price increases from suppliers (0.7%); higher sales of products acquired under the exclusive product line acquisitions (0.4%); and from the benefit of the stronger Euro during the period, since a relatively small proportion of our product costs are denominated in Euros (0.6%).
During the year our Business Development and Marketing teams combined to actively manage the margin achieved on sales and introduced a number of strategies aimed at working with suppliers to improve sales and manage cost increases.
Administrative expenses
Administrative expenses rose from £7.7m to £12.5m. This increase reflects the 37.2% growth in the average headcount to 166; the first full year of operation of the HTP facility; and the Japanese office. During the year a net impairment charge of £442k was taken to the income statement relating to the reduction in the carrying value of one of the exclusive product line acquisition deals, following an assessment of future prospects under the deal.
The bad debt provision increased from £224k to £591k during the year, largely as a result of an overseas distributor having financial difficulties after becoming involved in a local court action, meaning that recovery of the balance due is now considered doubtful.
Research and Development expenditure
Research and Development expenditure increased by 39.8%, reflecting an increase in investment in the development of the monoclonal production process and new polyclonal production development. The level of expenditure is expected to continue to increase in future as the level of new product polyclonal production grows and the monoclonal development programme scales-up.
Profit
Operating profits increased by 51.3% from £5.0m in the year ended June 2007 to £7.6m after adding back costs of £250k relating to a potential offer for the Group as announced to the market in July 2007. This represents an increase in operating profit as a percentage of sales from 20.5% to 20.8% despite the impact of the additional costs outlined above.
Interest income rose as the Company benefited from strong cash generation during the year.
Tax
The consolidated tax charge for the year was £2.1m or 25.9% of profit before tax reflecting the tax credits arising from the increased amount of research and development undertaken. A credit of £114k was also received for research and development activities undertaken in prior years. The effective tax charge for the year was 25.9% (2007 :26.6%).
The tax charge for 2007 was £1.5m having been restated from £1.6m following the adoption of International Financial Reporting Standards (IFRS). The consolidated tax charge will benefit in future from a full year’s impact of the reduction in corporation tax in the UK from 30% to 28% and an increased level of research and development.
Inventories
The Group manages stock levels closely by monitoring the expectations of future sales for every product in the catalogue, and the time taken to restock either from our own production or from OEM suppliers. As a result, stock levels have increased less than the growth in sales during the course of the year. Over time the Group expects the levels of stock to increase relative to sales since Abcam products developed in-house, involve batch sizes larger than required for immediate sale.
Debtors
A main focus for the year has been on debtor control and debtor days at the year end were 34.4 (2007: 44.3). The majority of sales continue to be on credit and we would expect some increase in debtor days over time in line with practice in local markets as the geographic spread of sales widens.
Creditors
Current liabilities rose from £3.4m to £4.8m primarily resulting from a 33.8% increase in trade and other payables, which is slightly less than the increase in sales. Non-current liabilities fell from £0.6m to £0.2m, being the net effect of a decrease in deferred tax balances due to the level of expenditure during the year on capital equipment relating to the HTP facility and a reduction in the estimated amount due as deferred settlement on a product line acquisition concluded in 2006.
Cashflow
The Group’s cashflow continues to be strong, with £7.1m (2007: £3.4m) generated from trading in the period. Consequently, despite spending £2.4m on facilities and equipment and £0.3m on acquiring distribution rights, the Group’s cash and short term investment balances increased by £3.8m.
Accounting standards
These are the first full year’s results of the Group to be stated under IFRS and consequently there are a number of changes to both presentation and content of these financial information. The effects of the adjustments are explained in note 30, the material changes being the inclusion of derivative instruments at fair value, giving rise to a charge to profit and loss of £197k (2007: charge of £168k) and the recognition of a deferred tax asset relating to unexercised share options of £224k (2007: liability of £46k).
EPS
The number of shares issued during the year for the exercise of share options was relatively small at 443,397 (2007: 158,800), meaning that as post tax profit grew by 43.7% (2007: 15.5%) the growth in basic EPS was 43.8% (2007: 5.7%) and diluted EPS was 44.9%.(2007: 6.5%)
Currency exposure
The Group continues to generate significant amounts of dollars and euros in excess of payments in these currencies, and has hedging arrangements in place to reduce the exposure. During the year to 30 June 2008 the Group had forward exchange contracts in place to sell $12.4m and €11.9m at average rates of £1 to $1.9356 and £1 to €1.4054 respectively. Of these, contracts for $4.2m and €4.5m were still outstanding at the year end.
For the year ending 30 June 2009 the Group has forward exchange contracts in place to sell $9.0m and €8.1m at average rates of £1 to $1.924 and €1.294.
Jeff Iliffe
Chief Financial Officer
8 September 2008

  

Abcam plc

Consolidated Income Statement

For the year ended 30 June 2008

Year ended

Year ended

Notes

30 June 2008

30 June 2007

Restated*

£000

£000

Revenue

5

36,694 

24,519 

Cost of sales

(14,389)

(10,020)

 

 

Gross profit

22,305 

14,499 

Administration and management expenses

(12,344)

(7,590)

 excluding share based compensation charge

 

 

Share based compensation charge

(173)

(142)

Total management and administration expenses

(12,517)

(7,732)

Research and development expenses

(2,398)

(1,709)

 excluding share based compensation charge

 

 

Share based compensation charge

(19)

(20)

Total research and development expenses

(2,417)

(1,729)

 

 

OPERATING PROFIT

7,371 

5,038 

Investment revenue

5

581 

495 

 

 

PROFIT BEFORE TAXATION 

7,952 

5,533 

Tax 

11

(2,062)

(1,472)

 

 

PROFIT FOR THE PERIOD FROM CONTINUING 

6,29

5,890 

4,061 

 OPERATIONS

Earnings per share

 from continuing operations - pence

Basic

13

16.88

11.74

Diluted 

13

16.56

11.43

*Restated to reflect the adoption of IFRS as per note 30.

All profit is attributable to equity holders of the parent.

  

Abcam plc

Consolidated statement of recognised income and expense

For the year ended 30 June 2008

Year ended

Year ended

30 June 2008

30 June 2007

£000

£000

(Losses)/gains on cash flow hedges

(168)

168

Exchange differences on translation of foreign operations

(28)

Deferred tax on outstanding share options

502 

(30)

Net income recognised directly in equity

337 

110 

Profit for the year

5,890

4,061

Total recognised income and expense for the year

6,227

4,171

  

Abcam plc

Consolidated Balance Sheet

At 30 June 2008

Notes

30 June 2008

30 June

2007

Restated*

£000

£000

Non-current assets

Intangible assets

14

994 

1,691 

Property, plant and equipment

15

4,204 

2,832 

5,198 

4,523 

Current assets

Inventories

17

4,506 

3,102 

Trade and other receivables

18

4,860 

4,327 

Cash and cash equivalents 

18

13,473 

10,709 

Short term deposits

18

1,020 

Derivative financial instruments

19

168 

23,859 

18,306 

Total Assets

29,057 

22,829 

Current Liabilities

Trade and other payables

21

(4,073)

(3,045)

Current tax liabilities

21

(382)

(248)

Provisions

22

(96)

(75)

Derivative financial instruments

19

(197)

(4,748)

(3,368)

Net current assets

19,111 

14,938 

Non-current liabilities

Deferred tax liabilities

20

(78)

(188)

Deferred creditor

21

(109)

(386)

(187)

(574)

Total liabilities

(4,935)

(3,942)

Net assets

24,122 

18,887 

Equity

Share capital

23,29

351 

346 

Share premium account

24,29

10,871 

10,619 

Share based compensation reserve

29

483 

251 

Deferred tax reserve

29

758 

256 

Translation reserve

29

(33)

(36)

Hedging reserve

29

168 

Retained earnings

29

11,692 

7,283 

Equity attributable to equity holders of the parent.

24,122 

18,887 

*Restated to reflect the adoption of IFRS as per note 30.

The financial information was approved by the board of directors and

authorised for issue on 8 September 2008.

They were signed on its behalf by:

Jeff Iliffe

Director

  

Abcam plc

Company Balance Sheet

At 30 June 2008

Notes

30 June 2008

30 June 2007

Restated*

£000

£000

Non-current assets

Intangible assets

14

994 

1,691 

Property, plant and equipment

15

3,976 

2,459 

Investments

16

45 

16 

5,015 

4,166 

Current assets

Inventories

17

4,501 

3,089 

Trade and other receivables

18

5,144 

4,572 

Cash and cash equivalents 

18

11,918 

10,055 

Short term deposits

18

1,020 

Derivative financial instruments

19

168 

22,583 

17,884 

Total Assets

27,598 

22,050 

Current Liabilities

Trade and other payables

21

(3,623)

(2,864)

Current tax liabilities

21

(269)

(243)

Provisions

22

(96)

(75)

Derivative financial instruments

19

(197)

(4,185)

(3,182)

Net current assets

18,398 

14,702 

Non-current liabilities

Deferred tax liabilities

20

(178)

(188)

Deferred creditor

21

(109)

(386)

(287)

(574)

Total liabilities

(4,472)

(3,756)

Net assets

23,126 

18,294 

Equity

Share capital

23,29

351 

346 

Share premium account

24,29

10,871 

10,619 

Share based compensation reserve

29

444 

251 

Deferred tax reserve

29

758 

256 

Hedging reserve

29

168 

Retained earnings

29

10,702 

6,654 

23,126 

18,294 

*Restated to reflect the adoption of IFRS as per note 30.

The financial information was approved by the board of directors and

authorised for issue on 8 September 2008.

They were signed on its behalf by:

Jeff Iliffe

Director

  

Abcam plc

Consolidated cash flow statement

For the year ended 30 June 2008

Year ended

Year ended

Notes

30 June 2008

30 June 2007

Restated*

£000

£000

Net cash from operating activities

28

7,142

3,426

Investing activities

Interest received

581 

495 

Proceeds on disposal of property,

 plant and equipment

(1)

Purchase of property,

 plant and equipment

(2,445)

(2,316)

Purchase of intangible

 assets

(274)

(1,848)

Net cash used in investing activities

(2,139)

(3,667)

Financing activities

Dividends paid

(1,481)

(968)

Proceeds on issue of shares

257 

47 

Increase in short term deposits

(1,020)

Net cash used in financing activities

(2,244)

(921)

Net increase/(decrease) in cash and cash equivalents

2,759 

(1,162)

Cash and cash equivalents at beginning 

 of year

10,709 

11,884 

Effect of foreign exchange rates

(13)

Cash and cash equivalents at end of year

13,473 

10,709 

*Restated to reflect the adoption of IFRS as per note 30.

  

Abcam plc

Company cash flow statement

For the year ended 30 June 2008

Year ended

Year ended

Notes

30 June 2008

30 June 2007

Restated*

£000

£000

Net cash from operating activities

28

5,858

2,736

Investing activities

Interest received

561 

504 

Proceeds on disposal of property,

 plant and equipment

Purchases of property,

 plant and equipment

(2,434)

(2,000)

Purchases of intangible

 assets

(251)

(1,848)

Investment in subsidiary

(29)

Dividends received

401 

269 

Net cash used in investing activities

(1,751)

(3,071)

Financing activities

Dividends paid

(1,481)

(968)

Proceeds on issue of shares

257 

46 

Increase in short term deposits

(1,020)

Net cash used in financing activities

(2,244)

(922)

Net increase/(decrease) in cash and cash equivalents

1,863 

(1,257)

Cash and cash equivalents at beginning 

 of year

10,055 

11,312 

Cash and cash equivalents at end of year

11,918 

10,055 

*Restated to reflect the adoption of IFRS as per note 30.

  

Abcam plc

Notes to the consolidated financial information

For the year ended 30 June 2008

1.General information

Abcam plc is a company incorporated in the England and Wales under the Companies Act 1985. 

The address of the registered office is 332 Cambridge Science Park, Milton RoadCambridge,

CB4 OFW United Kingdom.

The Group's activities consist of the development, marketing and selling of antibodies and closely

related products.The Group sells through the internet to customers in most countries of the

world. The Group operates through its parent company Abcam plc and through its wholly owned 

subsidiaries Abcam Inc. and Abcam KK.

This financial information is presented in pounds sterling because that is the currency of the 

Primary economic environment in which the Group operates. Foreign operations are included in 

accordance with the policies set out in note 2.

2.Significant accounting policies

Basis of Accounting

The financial information set out in the announcement does not constitute the company's statutory accounts for the years ended 30 June

2008 or 2007. The financial information for the year ended 30 June 2007 is derived from the statutory accounts for that year which have

been delivered to the Registrar of Companies. The auditors reported on those accounts; their report was unqualified, did not draw attention

to any matters by way of emphasis without qualifying their report and did not contain a statement under s237(2) or (3) Companies Act

1985.

Property, plant and equipment

Property, plant and equipment is stated at cost less depreciation and any provision for

impairment. Depreciation is provided at cost in equal instalments over the estimated lives 

of the fixed assets.

The depreciation rates applied are shown below:

Office equipment, fixtures and fittings

20% per annum

Laboratory equipment

20% per annum

Computer equipment

33% per annum

Hybridomas

33% per annum

Depreciation is accelerated if assets are deemed to have been impaired or there is a 

change in the residual economic life.The remaining useful lives of assets are re-assessed at each

balance sheet date.

Intangible assets

Expenditure on research activities is recognised as an expense in the period

in which it is incurred.

Payments made to acquire distribution rights from third parties are capitalised and

are amortised over the period of the agreement.

These assets are amortised on a straight line basis over their estimated minimum useful lives of 3 years.

Intangible assets are reviewed for impairment both annually and when there is an indication that 

an asset may be impaired when events or changes in circumstances indicate that the carrying 

value may not be recoverable. The assets' residual values, useful lives, and methods of 

valuation are reviewed and adjusted, if appropriate, at each financial year end.

Investments

Investments held as fixed assets are stated at cost less provision for any impairment in value.

Inventories

Inventories are stated at the lower of cost and net realisable value.Cost is calculated using the

actual cost of the product when acquired or manufactured.

The cost of Abcam own manufactured inventory includes material, direct labour and an attributable 

portion of production overheads based on normal levels of activity and is calculated using

the standard cost method.

Net realisable value is based on the estimated selling price less further costs expected

to be incurred to completion and disposal. Provision is made for obsolete, slow moving or 

defective items where appropriate.

Trade and other receivables

Trade receivables are measured at initial recognition at fair value. Appropriate allowances for

estimated irrecoverable amounts are recognised in the profit and loss account when there is 

objective evidence that the asset is impaired. When a trade receivable is considered uncollectible, 

it is written off against the allowance account. Subsequent recoveries of amounts previously written off

are credited against the allowance account. Changes in the carrying amount of the allowance

account are recognised in the income statement.

Derivative financial instruments

Forward contracts are used by the Group to manage its exposure to the risk associated with the variability 

in cash flows in relation to both recognised assets or liabilities and forecast transactions. All derivative 

financial instruments are measured at the balance sheet date at their fair value.

Where derivative financial instruments are not designated as or not determined to be effective 

hedges, any gain or loss on the remeasurement of the fair value of the instrument at the 

balance sheet date is taken to the income statement.

At the inception of the hedge relationship, the Group documents the

relationship between the hedging instrument and the hedged item, along with its risk 

management objectives and its strategy for undertaking various hedge transactions.

Furthermore, at the inception of the hedge and on an ongoing basis, the Group documents 

whether the hedging instrument that is used in a hedging relationship is effective in 

offsetting changes in cash flows of the hedged item.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges 

are recorded in the profit and loss immediately, together with any changes in the 

fair value of the hedged item that is attributable to the hedged risk. 

The effective portion of changes in the fair value of derivatives that are designated and qualify as

cash flow hedges are deferred in equity. The gain or loss relating to the ineffective portion

is recognised immediately in profit or loss and is included in the "other gains and losses" line of the 

income statement. Amounts deferred in equity are recycled in profit or loss in the periods

when the hedged item is recognised in profit or loss.

Hedge accounting is discontinued when the Group revokes the hedging relationship, the hedging 

instrument expires or is sold, terminated or exercised, or no longer qualifies for hedge accounting. 

The adjustment to the carrying amount of the hedged item arising from the hedged risk is amortised

to the profit and loss from that date and is included in the "other gains and losses" line of the 

income statement. Any cumulative gain or loss deferred in equity at that time

remains in equity and is recognised when the forecast transaction

is ultimately recognised in profit or loss. When a forecast transaction is no longer expected to occur,

the cumulative gain or loss that was deferred in equity is recognised immediately in profit or loss.

A derivative is presented as a non-current asset or non-current liability if the remaining maturity 

of the instrument is more than 12 months and is not expected to be realised or settled within 

12 months. Other derivatives are presented as current assets or liabilities.

Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net 

profit as reported in the income statement because it excludes some items of income 

or expense that are taxable or deductible in other years and it further excludes items that are

never taxable or deductible. The Group's liability for current tax is calculated using tax rates that 

have been enacted or substantively enacted by the balance sheet date.

Deferred tax is the tax expected to be payable or recoverable on differences between the 

carrying amount of assets and liabilities in the financial information and the corresponding tax 

bases used in the calculation of the taxable profit, and is accounted for using the balance sheet 

liability method. Deferred tax liabilities are generally recognised for all taxable temporary 

differences and deferred tax assets are recognised to the extent that it is probable that taxable 

profits will be available against which deductible temporary differences can be utilised. Such 

assets and liabilities are not recognised if the temporary difference arises from the initial 

recognition of goodwill or from the initial recognition of other assets and liabilities in a transaction

 that affects neither the taxable profit nor the accounting profit.

Deferred tax is calculated at the tax rates that are expected to apply in the period when the 

liability is settled or the asset is realised.

The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced 

to the extent that it is no longer probable that sufficient taxable profits will be available to allow 

all or part of the asset to be recovered. Deferred tax is charged or credited in the income

statement, except where it relates to items charged or credited directly to equity, in which 

case the deferred tax is also dealt with in equity.

Pensions

The Group operates a defined contribution pension scheme in the UK, which is 

open to all employees and directors of the company. 

The amount charged to the income statement in respect of pension costs is the contribution 

payable in the year. 

Any differences between contributions payable in the year, and contributions actually paid are 

shown either as accruals or prepayments in the balance sheet.

The amount included in the income statement in the year in respect of the pension scheme was £815,000

(2007:£253,000). The amounts included in creditors at 30 June 2008 in relation to the defined contribution

pension scheme is £65,000 (2007:£38,000)

Leases

Leases are classified as financial leases whenever the terms of the lease transfer substantially 

all the risks and rewards of ownership to the lessee. All other leases are classified as 

operating leases.

Rentals payable under operating leases are charged to income on a straight-line basis over the 

term of the relevant lease. Benefits received and receivable under an operating lease are also

spread on a straight-line basis over the lease term.

Assets held under finance leases are recognised as assets of the Group at their fair value or, if lower, 

at the present value of the the minimum lease payments, each determined at the inception of the lease. 

The corresponding liability to the lessor is included in the balance sheet as a finance lease obligation. Lease

payments are apportioned between finance charges and reduction of the lease obligation so as to achieve

a constant rate of interest on the remaining balance of the liability. Finance charges are charged directly

against income.

Foreign exchange

The individual financial information of each group company are presented in the currency of 

the primary economic environment in which it operates (its functional currency). For the

purposes of the consolidated financial information, the results and financial position of each

group company are expressed in pounds sterling which is the functional currency of the 

Company, and the presentation currency for the consolidated financial information.

In preparing the financial information of the individual companies, transactions in currencies

other than the entity's functional currency (foreign currencies) are recorded at the rates 

of exchange prevailing at the dates of the transactions. At each balance sheet date, monetary

assets and liabilities that are denominated in foreign currencies are retranslated to the rates 

prevailing at the balance sheet date. Non-monetary items carried at fair value are translated at 

the rates prevailing at the date when the fair value was determined. Non-monetary items 

that are measured in terms of historical cost in a foreign currency are not retranslated.

For the purpose of presenting consolidated financial information, the results 

of the operations of the Company's overseas subsidiaries, Abcam Inc and Abcam KK, are 

translated at the average rate of exchange during the period and their balance sheets at the 

rates ruling at the balance sheet date. Exchange differences arising on the translation of the 

opening net assets and results of operations are classified as equity and recognised in the 

Group's foreign currency translation reserve.

The treatment of exchange differences on transactions entered into to hedge certain foreign 

currency risks is detailed under derivative financial instruments above.

All other differences are included in the income statement in the period in which they arise.

Share Based Payments

The Group has applied the requirements of IFRS 2 Share-based payment. In accordance 

with the transitional provisions, IFRS 2 has been applied to all grants of equity instruments

after 7 November 2002 that were unvested at 1 July 2006.

The Group issues equity-settled share based payments to certain employees. Equity-settled 

share based payments are measured at the fair value (excluding the effect of non-market based 

vesting conditions) at the date of the grant. The fair value determined at the grant date of the 

equity-settled share based payments is expensed on a straight line basis over the vesting 

period, based on the Group's estimate of the number of shares that will eventually vest. There 

are both market and non-market based performance conditions attached to the vesting and

exercising of equity instruments. Fair value is measured by the use of the Monte Carlo 

Simulation. The expected life used in the model has been adjusted, based on management's 

best estimate, for the effects of the non-transferability, exercise restrictions and behavioural 

considerations. Charges made to the income statement in respect of share-based payments 

are credited to retained earnings.

Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable and represents

amounts receivable for goods and services provided in the normal course of business, net of 

discounts, VAT and other sales related taxes.

Sales of goods are recognised when goods are delivered and title has passed.

Interest income is accrued on a time basis, by reference to the principal outstanding and the 

effective interest rate applicable.

Dividend income from investments is recognised when the shareholders' rights to receive 

payment have been established.

Cash and cash equivalents 

Cash and cash equivalents comprise cash on hand and demand deposits, and other short term 

highly liquid investments that are readily convertible to a known amount of cash and are subject

to an insignificant risk of changes in value.

Trade and other receivables

Trade and other receiveables do not carry any interest and are stated at their nominal value as

reduced by appropriate allowances for estimated irrecoverable amounts.

Provisions

Provisions are recognised when the Group has a present obligation as a result of a past event, 

and it is probable that the Group will be required to settle the obligation at the balance sheet 

date, and are discounted to present value where the effect is material.

3.Critical accounting judgements and estimates

In the application of the Group's accounting policies, which are described in note 2, the Directors 

are required to make estimates and assumptions, in accordance with IFRS, that affect the 

amounts reported as assets and liabilities as at the date of reporting the financial information

and the reported amounts of revenues and expenditure during the year. In preparation of the 

consolidated financial information, estimates and assumptions have been made by the Directors

concerning the fair value of share options, the estimated useful lives of fixed assets, accruals 

and provisions required, the carrying value of investments, the recoverability of deferred tax 

assets, the carrying value of intangible assets and other similar evaluations. Actual amounts

that result could differ from those estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to 

accounting estimates are recognised in the period in which the estimate is revised if the revision

affects only that period, or in the period of the revision and future periods if the revision affects 

both current and future periods.

Key sources of estimation uncertaintly

The key assumptions concerning the future and, and other key sources of estimation uncertainty at the 

balance sheet date, that have a risk of causing a material adjustment to the carrying amounts of assets and liabilities

the most significant effect on the amounts recognised in financial information.

Impairment of intangibles

During the year,management renegotiated a product line agreement. Consequently, it was considered that

the carrying value of the intangible was overstated and it was adjusted to take account of the 

anticipated future sales and the risk associated with the contract.

Fair value of derivatives and other financial instruments

As described in Note 26, the directors use their judgement in selecting an appropriate valuation technique for financial 

instruments not quoted in an active market. Valuation techniques commonly used by market practioners

are applied. For derivative financial instruments, assumptions are made based on quoted market rates adjusted for 

specific features of the instrument. Other financial instruments are valued using a discounted cash flow analysis based 

on assumptions supported, where possible, by observable market prices or rates.

Valuation of own manufactured inventory

The standard costs used for the valuation of own manufactured inventory requires a number of assumptions concerning 

the allocation overheads. These assumptions are based primarily on managements estimates of time spent in 

each relevant area of activity.

Provision for obsolete stock

The provision for obsolete stock is based on managements estimation of the commercial life of inventory lines and 

is applied on a prudent basis. In assessing this, management takes in to consideration the sales history

of products and the length of time that they have been available for resale.

4.Income statement for the Company

The profit for the financial year dealt with in the financial information of the Company was £5,126,000

(2007:£3,687,000). 

5.Business and geographical segments

Geographical segments

The Group's operations are located in the UKUSA and Japan.

Business segments

The Directors consider that there are no identifiable business segments that are engaged in 

providing individual products or services or a group of related products and services that are 

subject to risks and returns that are different to the core business.

North

Europe

UK and

Japan

Total

America

rest of world

Year ended

Year ended

Year ended

Year ended

Year ended

30 Jun 2008

30 Jun 2008

30 Jun 2008

30 Jun 2008

30 Jun 2008

£000

£000

£000

£000

£000

Revenue

External sales

16,947 

10,748 

6,884 

2,115 

36,694 

Total revenue

16,947 

10,748 

6,884 

2,115 

36,694 

Result

Segment result

1,046 

5,198 

3,327 

215 

9,786 

Unallocated corporate expenses

(2,415)

Operating profit

7,371 

Investment revenues

581 

 

Profit before tax

7,952 

Tax

(2,062)

Profit after tax

5,890 

Other information

Capital additions

28 

2,744 

2,776 

Depreciation and amortisation

172 

1,255 

10 

1,437 

Impairment losses recognised 

 in income

642 

Balance sheet

Assets

Segment assets

2,946 

25,384 

727 

29,057 

Consolidated total assets

29,057 

Liabilities

Segment assets

(307)

(4,377)

(251)

(4,935)

Consolidated total liabilities

(4,935)

North

Europe

UK and

Japan

Total

America

rest of world

Year ended

Year ended

Year ended

Year ended

Year ended

30 Jun 2007

30 Jun 2007

30 Jun 2007

30 Jun 2007

30 Jun 2007

£000

£000

£000

£000

£000

Revenue

External sales

12,815 

5,899 

5,077 

728 

24,519 

Total revenue

12,815 

5,899 

5,077 

728 

24,519 

Result

Segment result

768 

3,254 

2,823 

(78)

6,767 

Unallocated corporate expenses

(1,729)

Operating profit

5,038 

Investment revenues

495 

 

Profit before tax

5,533 

Tax

(1,472)

Profit after tax

4,061 

Other information

Capital additions

285 

3,848 

31 

4,164 

Depreciation and amortisation

117 

673 

795 

Balance sheet

Assets

Segment assets

2,133 

20,131 

565 

22,829 

Consolidated total assets

22,829 

Liabilities

Segment liabilities

(154)

(3,107)

(31)

(3,292)

Consolidated total liabilities

(3,292)

6.Profit for the year

Profit for the year has been arrived at after charging (crediting):

Year 

Year 

ended

ended

30 Jun 2008

30 Jun 2007

£000

£000

Net foreign exchange losses/(gains)

136

(283)

Operating lease rentals - land and buildings (note 9)

545

237

Depreciation and amortisation of owned assets

1,437

795

Impairment loss on Intangible assets

642

Cost of inventories recognised as an expense

13,850

9,692

Write-down of inventories recognised as an expense

539

328

Staff costs (note 8)

7,308

5,250

Impairment loss recognised on trade receivables

367

153

Legal fees associated with proposed sale of group

250

Auditors' remuneration (note 7)

91

152

7.Auditors' remuneration

Year 

Year 

ended

ended

30 Jun 2008

30 Jun 2007

£000

£000

The analysis of the auditors' remuneration is as follows:

Fees payable to the company's auditors for 

 the audit of the company's annual accounts

75

79

Total audit fees

75

79

Fees payable to the company's auditors for 

 other services to the group

 -Tax services 

13

73

 -Employment benefits

3

Total non-audit fees

16

73

8.Staff costs

Group

The average monthly number of employees (including executive directors) was:

Year 

Year 

ended

ended

30 Jun 2008

30 Jun 2007

Management, administrative, marketing and distribution

130

101

Laboratory

36

20

166

121

Their aggregate remuneration comprised:

Year 

Year 

ended

ended

30 Jun 2008

30 Jun 2007

£000

£000

Wages and salaries

5,776

4,369

Social security costs

525

466

Pension costs

815

253

Charge in respect of share options granted

192

162

7,308

5,250

Company

The average monthly number of employees (including executive directors) was:

Year 

Year 

ended

ended

30 Jun 2008

30 Jun 2007

Number

Number

Management, administrative, marketing and distribution

88

69

Laboratory

36

20

124

89

Their aggregate remuneration comprised:

Year 

Year 

ended

ended

30 Jun 2008

30 Jun 2007

£000

£000

Wages and salaries

4,508

3,511

Social security costs

350

359

Other pension costs

776

233

Charge in respect of share options granted

162

162

5,796

4,265

9.Operating lease arrangements

Year 

Year 

ended

ended

30 Jun 2008

30 Jun 2007

£000

£000

Minimum lease payments under operating leases recognised as an expense

545

237

in the year

At the balance sheet date, the Group had outstanding commitments for future minimum lease payments

under non-cancellable operating leases, which fall due as follows: 

Group

30 Jun 2008

30 Jun 2007

£000

£000

Within one year 

651

197

In the second to fifth years inclusive

1,615

631

2,266

828

Company

30 Jun 2008

30 Jun 2007

£000

£000

Within one year 

392

197

In the second to fifth years inclusive

996

631

1,388

828

10.Other gains or losses 

Year 

Year 

ended

ended

30 Jun 2008

30 Jun 2007

£000

£000

Loss/(Gain) in fair value of forward exchange contracts 

 -On contracts used as hedging instruments

(1)

 -On other contracts

197

(see accounting policy note for derivative financial

instruments.)

11.Tax

Year 

Year 

ended

ended

30 Jun 2008

30 Jun 2007

£000

£000

Current tax 

1,632

1,159

Deferred tax (note 20)

430

313

2,062

1,472

Corporation tax is calculated at 29.5% (2007:30%) of the estimated assessable profit 

for the year.

Taxation for other jurisdictions is calculated at the rates prevailing in the respective jurisdictions.

The charge for the year can be reconciled to the profit per the income statement as follows:

Year 

Year 

Year 

Year 

ended

ended

ended

ended

30 Jun 2008

30 Jun 2008

30 Jun 2007

30 Jun 2007

£000

%

£000

%

Profit before tax 

7,952

 

5,533

 

Tax at the UK corporation tax rate 

 of 29.5% (2007: 30%)

2,346 

29.50%

1,660 

30.00%

Effect of different tax rates of subsidiaries

 operating in different jurisdictions

158 

1.99%

110 

1.99%

Tax effect of expenses that are not deductible

 in determining taxable profit

75 

0.94%

0.16%

R&D Tax credit uplift

(325)

-4.09%

(199)

-3.60%

Deduction for exercise for share options

(122)

-1.53%

(108)

-1.95%

Prior year adjustments

(70)

-0.88%

Tax expense and effective rate for the year 

2,062 

25.93%

1,472 

26.60%

12. Dividends

Year 

Year 

ended

ended

30 Jun 2008

30 Jun 2007

Amounts recognised as distributions to equity holders 

£000

£000

 in the year:

Final dividend for the year ended 30 June 2007

 of 3.19p (2006:2.00p) per share.

1,116

691

Interim dividend for the year ended 31 June 2008

 of 1.04p (2007:0.80p) per share.

365

277

1,481

968

Proposed final dividend for the year ended 

 30 June 2008 of 4.56p (2007:3.19 p) per share.

1,599

1,105

The proposed final dividend is subject to approval of the shareholders 

at the Annual General Meeting and has not been included as a liability 

in this financial information.

13. Earnings per share

The calculation of the basic and diluted earnings per share is based on the following data:

Year 

Year 

ended

ended

30 Jun 2008

30 Jun 2007

£000

£000

Earnings 

Earnings for the purposes of basic and diluted earnings 

5,890

4,061

 per share being net profit attributable to 

 equity holders of the parent.

Number of shares

Weighted average number of ordinary shares

 for the purposes of the basic earnings per share

34,902,538

34,572,810

Effect of dilutive potential ordinary shares:

 Share options

671,614

943,674

Weighted average number of ordinary shares for

 

 the purposes of diluted earnings per share.

35,574,152

35,516,484

Basic earnings per share is calculated by dividing the earnings attributable to ordinary

shareholders by the weighted average number of shares outstanding during the year.

Diluted earnings per share is calculated on the same basis as the basic earnings per share 

but with a further adjustment for the weighted average shares in issue to reflect the effect of all 

dilutive potential ordinary shares. The number of dilutive potential ordinary shares is derived from 

the number of share options granted to employees where the exercise price is less than the average 

market price of the Company's ordinary shares during the year.

14.Intangible assets 

Group and Company

Upfront

Distribution 

Total

licence fees

Rights

£000

£000

£000

Cost

At 1 July 2007

150

1,798

1,948

Additions

15 

237

252

Disposals

(1)

(1)

Revaluation for impairment

(642)

(642)

At 30 June 2008

164

1,393

1,557

Amortisation 

At 1 July 2007

68

189

257

Charge for the year

53

254

307

Disposals

(1)

(1)

At 30 June 2008

120

443

563

Carrying amount

At 30 June 2007

82

1,609

1,691

At 30 June 2008

44

950

994

The amortisation period for the upfront licence fees is 3 years.

The amortisation period for the distribution rights is the term of the deal.

The impairment loss is in respect of the reduction in the forecast revenues and profits of one of 

the distribution right agreement.

15. Property, plant and equipment

Group

Computer

Laboratory

Office

Hybridomas

Total

equipment

equipment

equipment

fixtures &

fittings

£000

£000

£000

£000

£000

Cost

At 1 July 2007

454

2,531

948

3,933

Additions

158

2,168

166

22

2,514

Exchange differences

4

1

2

7

Disposals

(28)

(21)

(5)

(54)

At 30 June 2008

588

4,679

1,111

22

6,400

Accumulated depreciation

At 1 July 2007

218

346

537

1,101

Charge for the year

149

709

269

3

1,130

Exchange differences

(23)

(9)

(5)

(37)

Eliminated on disposals

1

1

2

At 30 June 2008

345

1,046

802

3

2,196

Carrying amount

At 30 June 2007

236

2,185

411

2,832

At 30 June 2008

243

3,633

310

19

4,204

Company

Computer

Laboratory

Office

Internally

Total

equipment

equipment

equipment

generated

fixtures &

assets

fittings

£000

£000

£000

£000

£000

Cost

At 1 July 2007

344

2,286

750

3,380

Additions

143

2,161

156

22

2,482

Disposals

(26)

(20)

(2)

(48)

At 30 June 2008

461

4,427

904

22

5,814

Accumulated depreciation

At 1 July 2007

180

292

449

921

Charge for the year

113

660

172

3

948

Eliminated on disposals

(21)

(9)

(1)

(31)

At 30 June 2008

272

943

620

3

1,838

Carrying amount

At 30 June 2007

164

1,994

301

2,459

At 30 June 2008

189

3,484

284

19

3,976

16. Investments

The company's subsidiaries at 30 June 2008 are:

Proportion

Proportion 

Country of

of shares

of voting 

incorporation

held

power held

Abcam Inc

USA

100%

100%

Abcam KK

Japan

100%

100%

Camgene

UK

100%

100%

Abcam Inc and Abcam KK are involved in the sale and distribution of antibodies.

Camgene is dormant.

Analysis of changes in Investments

£000's

Cost

At 1 July 2007

16

Additions

29

At 30 June 2008

45

Investments are held at cost less provision for impairment. All additions represent share based payment

charges for share options issued by the company to employees of the subsidiaries.

17. Inventories

Group

Company

Group

Company

30 Jun 2008

30 Jun 2008

30 Jun 2007

30 Jun 2007

£000

£000

£000

£000

Goods for resale

4,506

4,501

3,102

3,089

18. Financial assets

Group

Company

Group

Company

30 Jun 2008

30 Jun 2008

30 Jun 2007

30 Jun 2007

£000

£000

£000

£000

Trade and other receivables:

Amounts receivable for the sale of goods

4,288 

2,470 

3,539 

1,905 

Allowance for doubtful debts

(591)

(413)

(224)

(197)

3,697 

2,057 

3,315 

1,708 

Owed by subsidiary undertakings

2,169 

1,461 

Other debtors

499 

292 

543 

979 

Prepayments

664 

626 

469 

424 

4,860 

5,144 

4,327 

4,572 

The average credit period taken for sales is 34.4 days (2007:44.3 days). No interest is charged on the receivables.

Trade receivables are provided for based on estimated irrecoverable amounts determined by reference to past 

default experience. The group and company have provided fully for all amounts over 120 days because historical experience

is such that receivables that are past due 120 days are not generally recoverable. Trade receivables between

30 days and 120 days are provided for based on estimated irrecoverable amounts from the sale of 

goods determined by reference to past default experience.

Credit limits for each customer are reviewed on a monthly basis. There are no customers 

who represent more than 5% of the total balance of trade receivables.

The analysis below show the balances included in debtors which are past due at the

reporting date for which the group or company has not provided as there has not

been a significant change in credit quality and the amounts are still considered

recoverable.

Ageing of past due but not impaired receivables

Group

Company

Group

Company

30 Jun 2008

30 Jun 2008

30 Jun 2007

30 Jun 2007

£000

£000

£000

£000

30-60 days

242

111

297

144

60-90

48

48

231

121

>90 days

331

181

Total

290

159

859

446

During the year the Group has formalised and improved the credit control procedures. This has resulted in a 

noticeable improvement in the ageing of the debtors.

Movement in the allowance for doubtful debts

Group

Company

Group

Company

30 Jun 2008

30 Jun 2008

30 Jun 2007

30 Jun 2007

£000

£000

£000

£000

Balance at the beginning of the year

224

198

85

46

Impairment losses recognised

367

215

139

152

Balance at the end of the year

591

413

224

198

In determining the recoverability of a trade receivable the Group and Company consider any change in 

the credit quality of the receivable from the date credit was initially granted up to the 

reporting date. The concentration of credit risk is limited due to the customer base being large

and unrelated. Accordingly the directors believe that there is no further credit provision

required in excess of the allowance for doubtful debts.

Included in the allowance for doubtful debts are individually impaired trade receivables

with a balance of £289,000 (2007: £121,000) relating to companies in financial

difficulties.

The impairment recognised represents the difference between the carrying amount of these 

trade receivables and the present value of the expected litigation proceeds. 

Neither the Group or the Company hold collateral over these balances.

Ageing of impaired receivables

30 Jun 2008

30 Jun 2007

£000

£000

60-90 days

38

>90 days

553

224

Total

591

224

The directors consider that the carrying amount of trade and other receivables approximates

their fair value.

Cash and cash equivalents

Group

Company

Group

Company

30 Jun 2008

30 Jun 2008

30 Jun 2007

30 Jun 2007

£000

£000

£000

£000

Cash and cash equivalents

14,493

12,938

10,709

10,055

Cash and cash equivalents comprise cash held by the group and short-term deposits with 

an original maturity of three months or less. The carrying amount of these assets 

approximates their fair value.

19. Derivative financial instruments

Group and Company

Current

30 Jun 2008

30 Jun 2007

£000

£000

Derivatives that are designated and

effective as hedging instruments

carried at fair value

Forward exchange contracts

168

Derivatives carried at fair value through

profit and loss (FVTPL)

Forward exchange contracts

(197)

(197)

168

On 22 April 2008, all hedging instruments were de-designated and the fair value

adjustments on the outstanding forward exchange contracts were charged through the profit and loss.

20. Deferred tax

The following are the major deferred tax liabilities and assets recognised by the Group 

and movements thereon during the current and prior reporting period.

Group

Accelerated

Share based

Other timing

Total

tax

payment

differences

depreciation

£000

£000

£000

£000

At 1 July 2006

(152)

317 

40 

205 

Charge to income

(397)

46 

15 

(336)

Charge to equity

(57)

(57)

 

 

 

 

At 30 June 2007

(549)

306 

55 

(188)

Charge to income

(332)

(224)

126

(430)

Credit to equity

540 

540 

 

 

 

 

At 30 June 2008

(881)

622 

181 

(78)

Company

Accelerated

Share based

Other timing

Total

tax

payment

differences

depreciation

At 1 July 2006

(152)

317 

40 

205 

Charge to income

(397)

46 

15 

(336)

Charge to equity

(57)

(57)

 

 

 

 

At 30 June 2007

(549)

306 

55 

(188)

Charge to income

(338)

54 

54

(230)

Credit to equity

240 

240 

 

 

 

 

At 30 June 2008

(887)

600 

109 

(178)

At the balance sheet date, the aggregate amount of temporary differences associated with undistributable 

earnings of subsidiaries for which a deferred tax liability has not been recognised is £1,028,000 

(2007: £595,000). No liability has been recognised in respect of these differences because the

Group is in a position to control the timing of the reversal of temporary differences and it is probable

that such differences will not reverse in the foreseeable future.

21.Other financial liabilities

Group

Company

Group

Company

30 Jun 2008

30 Jun 2008

30 Jun 2007

30 Jun 2007

£000

£000

£000

£000

Trade and other payables

Trade creditors and accruals

3,638 

3,221 

2,474 

2,309 

Deferred creditor

86 

86 

110 

110 

Corporation tax

382 

269 

248 

243 

Other taxes and social security

160 

159 

124 

124 

Other creditors

189 

157 

337 

321 

4,455 

3,892 

3,293 

3,107 

Trade creditors and accruals principally comprise amounts outstanding for trade purchases and 

ongoing costs. The average credit period taken for trade purchases is 17 days (2007: 32 days). 

At the end of the previous financial year, it was decided that supplies should be paid on a more

frequent basis.

Most suppliers do not charge interest for the first 60 days of the invoice. The Group has financial risk

management policies in place to ensure that all payables are paid within the credit time frame.

The deferred creditor represents the earn-out payable on sales of products under a distribution agreement

(see note 14) .The portion payable in more than 12 months is included in non-current liabilities.

(2008: £109,000 2007: £386,000)

The directors consider that the carrying amount of the trade and other payables approximates to their 

fair value.

22. Provisions

Group

Company

Group

Company

30 Jun 2008

30 Jun 2008

30 Jun 2007

30 Jun 2007

£000

£000

£000

£000

Amounts payable

 under the loyalty scheme

Opening balance

75

75

45

45

Awarded in year 

314

314

245

245

Expired in year

(184)

(184)

(133)

(133)

Redeemed in year

(109)

(109)

(82)

(82)

Closing balance

96

96

75

75

This represents amounts awarded to customer under a loyalty scheme.

23. Share Capital

Group and Company

30 Jun 2008

30 Jun 2007

£000

£000

Authorised:

1,000,000 ordinary shares of 1p each

1,000

1,000

Issued and fully paid:

35,066,781 (2007:34,623,384) ordinary shares of 1p each

351

346

The Company operates a number of share option schemes for certain employees of the Group. Details 

are provided in note 25.

24. Share Premium

Group and Company

£000

Balance at 1 July 2006

10,573

Premium arising on issue of equity shares

46

Balance at I July 2007

10,619

Premium arising on issue of equity shares

252

Balance at 30 June 2008

10,871

There were no costs of issue.

25.Share-based payments

Equity-settled share option scheme

The Company operates a number of share option schemes for certain employees of the Group.

The share based compensation charge is made up from option awards from the EMI plan, Unapproved 

share option plan, the US employees share option plan and the SAYE plan. Option grants under

each scheme have been aggregated.

The vesting period is from 1 - 3 years other than for those options with performance criteria, which vest 

when the criteria are met. If the options remain unexercised after a period of ten years from the date of 

grant the options expire. Options are forfeited if the employee leaves the Group before the options vest. 

The fair value of the options at the date of grant is the market price.

The volatility of the options is based on the long term average volatility in the share price of five quoted 

companies that are considered to have a reasonable comparability with Abcam plc.

The dividend yield is based on Abcam's actual dividend yield in the past.

The risk free rate is the yield on UK Government Gilts at each date of grant.

The employee exercise multiple is based on published statistics for a portfolio of companies.

The employee exit rate is based on management's expectations and, in accordance with IFRS 2, is 

applied after vesting.

Details of the share options outstanding during the year are as follows:

Summary of all schemes

Options outstanding as at 30 June 2008 had an exercise price of between 10p and 413p (2007:10p and 280p)

The weighted average remaining contractual life is 8.12 years (2007:5.92 years). The weighted average

fair value of the options outstanding at the end of the year was 65.24p (2007:46.27p)

The Group recorded total expenses of £191,000 (2007: 162,000)

2008

2007

No. of

Weighted

No. of

Weighted

Share options

average

Share options

average

exercise price

exercise price

p

p

Outstanding at beginning of year

1,497,902

152.83

1,085,160

47.40

Granted during the year

514,349

320.08

651,393

280.00

Forfeited during the year

(260,287)

233.19

(79,851)

280.00

Exercised during the year

(441,815)

57.37

(158,800)

30.00

Outstanding at the end of the year

1,310,149

219.32

1,497,902

152.83

Exercisable at end of year

302,640

43.07

657,960

20.00

Enterprise management incentive scheme

2008

2007

No. of

Weighted

No. of

Weighted

Share options

average

Share options

average

exercise price

exercise price

p

p

Outstanding at beginning of year

966,191

131.51

768,480

39.20

Granted during the year

284,851

312.00

352,240

281.40

Forfeited during the year

(90,177)

161.41

(37,089)

280.00

Exercised during the year

(327,337)

53.80

(117,440)

31.80

Outstanding at the end of the year

833,528

206.94

966,191

131.51

Exercisable at end of year

262,640

40.11

547,040

28.00

The growth in the net assets of the Group means that Group will shortly exceed the limits set by the

Inland Revenue for the tax incentives available under the Enterprise management incentice scheme.

Unapproved share option scheme

2008

2007

No. of

Weighted

No. of

Weighted

Share options

average

Share options

average

exercise price

exercise price

p

p

Outstanding at beginning of year

427,504

194.71

261,360

82.60

Granted during the year

148,338

340.30

168,246

292.70

Forfeited during the year

(137,375)

288.34

(742)

280.00

Exercised during the year

(83,558)

71.76

(1,360)

62.50

Outstanding at the end of the year

354,909

223.66

427,504

194.71

Exercisable at end of year

40,000

62.50

80,000

0.00

Abcam Inc share scheme

2008

2007

No. of

Weighted

No. of

Weighted

Share options

average

Share options

average

exercise price

exercise price

p

p

Outstanding at beginning of year

104,207

185.56

55,320

62.50

Granted during the year

81,160

312.00

90,907

280.00

Forfeited during the year

(32,735)

312.00

(42,020)

248.74

Exercised during the year

(30,920)

56.33

Outstanding at the end of the year

121,712

291.47

104,207

185.56

Exercisable at end of year

30,920

0.00

During the year the company issued 1p ordinary shares as follows:

Date issued

Number

Exercise 

Total 

of shares

Price

Paid

p

£

Oct-07

760

10.0

76

Oct-07

20,640

25.0

5,160

Oct-07

32,000

37.5

12,000

Oct-07

235,080

62.5

146,933

Nov-07

61,800

25.0

15,450

Nov-07

20,000

30.0

6,000

Dec-07

7,200

25.0

1,800

Dec-07

2,120

62.5

1,325

Feb-08

14,495

280.0

40,586

Mar-08

10,000

25.0

2,500

Mar-08

3,640

56.3

2,049

Mar-08

4,040

62.5

2,525

Apr-08

9,160

56.3

5,157

Apr-08

2,760

62.5

1,725

May-08

18,120

56.3

10,202

May-08

1,582

*

224.0

3,544

443,397

257,032

*Issued under SAYE scheme.

Fair value calculation:

The fair value of the options schemes, other than those options with market based performance criteria,

has been calculated using the Trinomial method. The inputs into the Trinomial model are as follows:

EMI Scheme

Grant date

16.6.03

16.6.03

5.7.04

17.12.04

27.5.05

5.9.05

Share price at grant -pence

10

10

25

30

62.5

62.5

Fair value at valuation date -pence

2.6

2.6

8.5

12.3

19.2

19.1

Exercise price -pence

25

37.5

25

25

62.5

62.5

Expected volatility

40%

40%

35%

35%

30%

30%

Expected life -years

3

3.08

2

2.88

2

2

Expected dividend yield

1.1

1.1

1.1

1.1

1.1

1.1

Risk free rate

3.97%

3.97%

5.08%

4.49%

4.31%

4.15%

Employee exercise multiple

2

2

2

2

2

2

Employee exit rate

10.00%

10.00%

10.00%

10.00%

10.00%

10.00%

Unapproved scheme

Grant date

20.12.04

20.12.04

30.9.05

30.9.05

27.10.05

Share price at grant -pence

30

30

62.5

62.5

167

Fair value at valuation date -pence

11.2

11.6

18.9

10.2

55.77

Exercise price -pence

25

25

62.5

125

150

Expected volatility

35%

35%

30%

30%

30%

Expected life -years

1.54

2

1.82

1.82

1.635

Expected dividend yield

1.1

1.1

1.1

1.1

1.1

Risk free rate

4.46%

4.46%

4.29%

4.29%

4.40%

Employee exercise multiple

2

2

2

2

2

Employee exit rate

10.00%

10.00%

10.00%

10.00%

10.00%

The fair value of options issued after September 2006, with market based performance criteria, are calculated 

using the Monte Carlo model. 

The inputs into the Monte Carlo model are as follows:

Grant date

7.9.06

8.11.07

7.5.08

Share price at grant -pence

280

312

413

Fair value at valuation date -pence

84

0.59

1.23

Exercise price -pence

280

312

413

Expected volatility

30%

30%

30%

Expected life -years

3

3.01

3

Expected dividend yield

1.1

1.5

1.5

Risk free rate

4.57%

4.80%

4.79%

Employee exercise multiple

2

2

2

Employee exit rate

9.53%

12.00%

12.00%

26. Financial Instruments

Capital Risk Management

The Group manages its capital to ensure that entities in the Group will be able to continue as

going concerns whilst maximising the return to stakeholders through the optimisation of 

the debt and equity balance. The capital structure of the Group consists of cash and cash 

equivalents and equity attributable to the equity holders of the parent, comprising issued

capital, reserves and retained earnings as disclosed in the Consolidated Statement of changes in 

Equity.

Significant accounting policies

Details of the significant accounting policies and methods adopted, including the criteria 

for recognition, the basis of measurement and the basis on which income and expenses

are recognised, in respect of each class of financial asset, financial liability and 

equity instrument are disclosed in relevant note to the financial information.

Categories of financial instruments

All financial instruments are held for trading.

Group

Company

Carrying value

Carrying value

30 Jun 2008

30 Jun 2007

30 Jun 2008

30 Jun 2007

£000

£000

£000

£000

Financial assets

Loans and receivables

Amounts owed by Group undertakings

2,033

1,461

Trade receivables

3,697

3,315

2,057

1,708

VAT Recoverable

234

440

234

440

 (included in other debtors)

3,931

3,755

4,324

3,609

Cash and cash equivalents

Deposits held to maturity

12,587

8,500

11,520

8,500

Cash and cash equivalents

1,906

2,209

1,418

1,555

14,493

10,709

12,938

10,055

Financial liabilities

Other financial liabilities at amortised cost

Amounts owed by Group undertakings

93

Trade payables

1,994

1,719

1,784

1,324

Corporation tax payable

382

248

269

564

Other taxes and social security

160

124

160

124

Accruals

2,014

1,277

1,680

1,170

Deferred creditor

110

386

110

386

 (shown under Non-Current liabilities)

4,660

3,754

4,096

3,568

The Directors consider there to be no material difference between the book value and the fair value of the 

Group's financial assets and liabilities.This is because most of the financial assets and liabilities are

short term.

Risk in relation to the use of financial instruments

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in

financial loss to the Group or the Company.

Trade receivables consist of a large number of customers spread across diverse geographical areas.

The Group does not have any significant credit risk exposure to any single counterparty. Ongoing

credit evaluation is performed on the financial condition of accounts receivable and consideration. 

is given as to whether there is any impairment in the value of any amounts owing.

The standard payment terms for receivables other than intra-group balances are 30 days. 

Any variation in these terms requires authorisation by senior management. Year end debtor days are 34.4 (2007:44.3).

All overdue debts are provided for where collectability is considered doubtful or the value of the debt is impaired.

Objective evidence of impairment could include the Group's past experience of collecting payments, an increase

in the number of delayed payments in the portfolio past the average credit period of 34.4 days, as well as

observable changes in international or local economic conditions.

The standard payment terms for intragroup receivables is 45 days. There is not considered to be any risk of

impairment of these receivables unless the financial assets of the entity holding the corresponding liability

are impaired.

The credit risk on liquid funds and derivative financial instruments is limited because the counterparties 

are banks with high credit-ratings assigned by international credit-rating agencies. Funds are split between 

at least two institutions.

Market risk

The Group's activities expose it primarily to the financial risks of changes in foreign currency 

exchange rates and interest rates. The Group enters into forward exchange contracts to hedge

the exchange rate risk arising on the sales of goods and services denominated in Dollars and Euros. 

Foreign currency risk management

The Group undertakes certain transactions denominated in foreign currencies. 

The Group's policy is to maintain natural hedges, where possible, by matching foreign currency

revenue and expenditure. 

Exchange rate exposures are managed within approved policy parameters utilising forward 

exchange contracts.

The carrying amounts of the Group's foreign currency denominated monetary assets and liabilities

at the reporting date are as follows:

Liabilities

Assets

30 Jun 2008

30 Jun 2007

30 Jun 2008

30 Jun 2007

£000

£000

£000

£000

Euros

79

79

1,655

1,183

Dollars

821

752

3,886

1,511

Yen

17

32

539

455

917

863

6,080

3,149

Foreign currency sensitivity analysis

The Group's principal functional currency is pound sterling. The Group is mainly exposed to US dollars 

and Euros but has an increasing exposure to Japanese Yen.

The following table details the Group's sensitivity to an 8% increase and decrease in Sterling against 

the relevant foreign currencies. 8% is considered by management to be a reasonably possible

change in foreign exchange rates after giving consideration to changes in exchange rates over the last 

12 months.

The sensitivity analysis includes only outstanding foreign currency

denominated financial assets and liabilities and the cash flow hedging reserve and adjusts their translation 

at the period end for an 8% change in foreign exchange rates. The analysis below shows the increase or

decrease in profit and the change in equity when the Sterling weakens or strengthens 8% against the relevant currency.

Euro currency impact

Dollar currency impact

2008

2007

2008

2007

£000

£000

£000

£000

Impact of 8% strengthening

 - foreign currency financial assets

(117)

(82)

(227)

(56)

and liabilities

 -Cash flow hedging reserve

316 

176 

Impact of 8% weakening

 - foreign currency financial assets

137 

96 

266 

66 

and liabilities

 -Cash flow hedging reserve

(396)

(562)

The Group's sensitivity to foreign currency has increased during the period due to increased sales

levels. This increase has been proportionately more than the increase in dollar purchases.

In management's opinion, the sensitivity analysis is representative of the inherent foreign exchange risk 

at year end. 

The Group's policy is to maintain natural hedges, where possible, by matching

USD revenue with USD expenditure.

Forward exchange contracts

It is the policy of the Group to enter into forward exchange contracts to manage the risk associated 

with anticipated sales transactions within 30% to 80% of the exposure generated.

The Group uses a rolling hedging strategy with contracts with terms up to 12 months. Upon

maturity of a forward contract, the Group may enter in to a new contract designated as a separate 

hedging relationship.

Foreign currency forward contracts are measured using quoted forward exchange rates matching

maturities of the contracts.

Average

Foreign 

Contract

Fair

Outstanding contracts

rate

currency

value

value

30 Jun 2008

30 Jun 2008

30 Jun 2008

30 Jun 2008

£000's

£000's

£000's

Sell US Dollars

Less than 3 months

1.97

$1,200

608

3

3 to 6 months

1.96

$2,400

1,222

2

7 to 12 months

1.94

$600

309

2

1.96

$4,200

2,139

7

Sell Euros

Less than 3 months

1.33

€ 1,700

1,278

(70)

3 to 6 months

1.34

€ 2,800

2,088

(133)

7 to 12 months

1.34

€ 4,500

3,366

(203)

Total of outstanding forward contracts

5,505

(196)

30 Jun 2007

30 Jun 2007

30 Jun 2007

30 Jun 2007

£000's

£000's

£000's

Sell US Dollars

Less than 3 months

1.92

$1,200

624

25

3 to 6 months

1.92

$2,250

1,171

46

7 to 12 months

1.76

$3,950

2,245

85

1.83

$7,400

4,040

156

Sell Euros

Less than 3 months

1.48

€ 400

268

3 to 6 months

1.47

€ 3,950

2,685

4

7 to 12 months

1.46

€ 2,100

1,441

8

1.47

€ 6,450

4,394

13

Total of outstanding forward contracts

8,434

169

The analysis below shows the increase or decrease in profit and the change in equity when the 

Sterling weakens or strengthens 8% against the relevant currency.

2008

2007

£000's

£000's

Fair value of outstanding contracts should sterling

strengthen by 8%

US Dollars

154 

176 

Euros

440 

316 

594 

492 

2008

2007

£000's

£000's

Fair value of outstanding contracts should sterling

weaken by 8%

US Dollars

(196)

(562)

Euros

(72)

(396)

(268)

(958)

At 30 June 2007, all of the contracts were held as cash flow hedges.

At 30 June 2008, none of the contracts were held as cash flow hedges.

Liquidity risk management

Ultimate responsibility for liquidity risk management rest with the board of directors, which has built 

an appropriate liquidity risk management framework for the management of the Group's short, medium

and long-term funding and liquidity management requirements. The Group manages liquidity risk by 

maintaining adequate reserves and banking facilities by continuously monitoring cash flows and 

matching the maturity profiles of financial assets and liabilities.

The Group and Company hold cash deposits at call or with a maturity of up to 12 months.

At 30 June 2008, the average maturity of balances was 35 days of fixed rate deposits not

sensitive to changes in interest rates.

All funds are readily available to the Company to meet operational requirements.

The amount owing from subsidiaries is payable on demand and is classified as being payable within 1

month.

Trade payables are normally payable within 30 days of invoice.

Liquidity and interest risk tables -financial liabilities

(All balances are capital and do not include accrued interest)

Weighted

average

On demand

1 to 3 

3 months

Total

interest

1 month

months

to 1 year

rate

%

£000's

£000's

£000's

£000's

Group

2008

Trade payables

1,110

603

4

1,717

Accruals

1,561

474

2,035

2,671

603

478

3,752

Company

2008

Trade payables

1,610

25

1,635

Accruals

1,284

418

1,702

2,894

25

418

3,337

Group

2007

Trade payables

1,184

225

1,409

Accruals

988

262

1,250

2,172

225

262

2,659

Company

2007

Trade payables

1,194

217

1,411

Accruals

848

235

1,083

2,042

217

235

2,494

Interest rate risk sensitivity analysis

An increase in 1% in the average interest rate during the year would have resulted in an increase

in interest received by the Group of £113,000 (2007:£111,000) and by the Company of £103,000 (2007:£111,000)

A decrease in 1% in the average interest rate during the year would have resulted in an equal

and opposite impact on interest received by the Group and the Company as described above.

Fair value of financial instruments

The fair values of the financial assets and liabilities are determined as follows:

Foreign exchange contracts are measured using quoted forward exchange rates and the yield curves

derived from quoted interest rates matching maturities of these contracts.

The Directors consider there to be no material difference between the book value and the fair value of 

the Group's financial assets and liabilities at the balance sheet date. This is because most of the 

financial assets and liabilities are short term.

27.Related party transactions

Under a New Product Development agreement with a laboratory associated with Tony Kouzarides, 

(a non-executive director of the company) Abcam provided products from its catalogue free of charge, with 

a resale value of £16,714 (2007:£14,000) and paid £36,148 in royalties (2007:£23,000).£6,632 of these 

royalties were outstanding at year end (2007:£7,000).

Eddie Powell, who retired as Finance Director on 20 November 2007 was subsequently 

employed as an independent contractor for which he was paid £15,322.

Remuneration of key personnel

The remuneration of the Directors, who are the key management personnel of the Group, is set out

 below in aggregate for each of the categories specified in IAS 24 "Related Party Disclosures".

Group and Company

2008

2007

30 Jun 2008

30 Jun 2007

Short term employee benefits and fees

1,221

843

Share-based payment

50

29

1,271

872

28.Notes to the cash flow statement

Group

30 Jun 2008

30 Jun 2007

000's

000's

Operating profit for the year

7,371

5,038

Adjustments for:

Depreciation of property,plant and equipment

1,092

561

Impairment losses on intangible assets

642

Amortisation of intangible assets

309

234

Share based compensation charge

232 

163

Operating cash flows before movements 

9,646

5,996

in working capital

Increase in inventories

(1,405)

(744)

Increase in receivables

(533)

(1,566)

Increase in payables

772 

1,045 

Decrease in derivative 

 financial instruments

365 

(Decrease)/Increase in hedging reserve

(168)

168 

Cash generated by operations

8,677

4,899

Income taxes paid

(1,535)

(1,473)

NET CASH FROM OPERATING

7,142

3,426

 ACTIVITIES

Company

30 Jun 2008

30 Jun 2007

000's

000's

Operating profit for the year

6,113

4,343

Adjustments for:

Depreciation of property,plant and equipment

917

439

Impairment losses on intangible assets

642

Amortisation of intangible assets

306

234

Share based compensation charge

192 

163

Operating cash flows before movements 

8,170

5,179

in working capital

Increase in inventories

(1,412)

(741)

Increase in receivables

(572)

(1,896)

Increase in payables

503 

1,031 

Decrease in derivative 

 financial instruments

365 

(Decrease)/increase in hedging reserve

(168)

168 

Cash generated by operations

6,886

3,741

Income taxes paid

(1,028)

(1,005)

NET CASH FROM OPERATING

5,858

2,736

 ACTIVITIES

29.Reconciliation of movements in equity

Group

Share 

Share 

Translation

Share-based

Hedging 

Deferred 

Retained 

Total

capital

premium

reserve

compensation

reserve

tax reserve

earnings

reserve

1

2

3

4

£000's

£000's

£000's

£000's

£000's

£000's

£000's

£000's

Balance as at 1 July 2006

345 

10,573 

(8)

89 

286 

4,190 

15,475 

Exchange differences on

(28)

(28)

translating foreign operations

Share-based compensation

162 

162 

Deferred tax on outstanding 

(30)

(30)

share options

Profit for the year

4,061 

4,061 

Total income / expense for 

(28)

162 

(30)

4,061 

4,165 

the year

Issue of share capital

46 

47 

Movement on hedging

168 

168 

reserve for the adoption of hedge accounting

Payment of dividends

(968)

(968)

(note 12)

Balance as at 30 June 2007

346 

10,619 

(36)

251 

168 

256 

7,283 

18,887 

Exchange differences on translating

foreign operations

Share-based compensation

232 

232 

Deferred tax on outstanding share options

502 

502 

 share options

Profit for the year

5,890 

5,890 

Total income / expense for

232 

502 

5,890 

6,627 

the year

Issue of share capital

252 

257 

Utilisation of derivative

(168)

(168)

instruments

Payment of dividends

(1,481)

(1,481)

(note 12)

Balance as at 30 June 2008

351 

10,871 

(33)

483 

758 

11,692 

24,122 

1. Exchange differences on translation of overseas operations

2. IFRS 2 Charge for fair value of share options

3. Gains and losses recognised on cash flow hedges

4. Portion of deferred tax asset arising on outstanding share options and share options exercised

and not taken to profit and loss in accordance with IAS12.

Company

Share 

Share 

Share-based

Hedging 

Deferred 

Retained 

Total

capital

premium

compensation

reserve

tax reserve

earnings

reserve

1

2

3

£000's

£000's

£000's

£000's

£000's

£000's

£000's

Balance as at 1 July 2006

345 

10,573 

89 

286 

3,663 

14,956 

Share-based compensation

162 

162 

Deferred tax on outstanding

(30)

(30)

share options

 Profit for the year

3,687 

3,687 

Total income / expense for

162 

(30)

3,687 

3,819 

the year

 Issue of share capital

46 

47 

Movement on hedging

168 

168 

reserve for the adoption of hedge accounting

Payment of dividends

(968)

(968)

(note 12)

Receipt of dividends

272 

272 

Balance as at 30 June 2007

346 

10,619 

251 

168 

256 

6,654 

18,294 

Share-based compensation

193 

193 

Deferred tax on outstanding

502 

502 

share options

Profit for the year

5,126 

5,126 

Total income / expense for

193 

502 

5,126 

5,821 

the year

Issue of share capital

252 

257 

Utilisation of derivative

(168)

(168)

instruments

Payment of dividends

(1,481)

(1,481)

(note 12)

Receipt of dividends

403 

403 

Balance as at 30 June 2008

351 

10,871 

444 

758 

10,702 

23,126 

1. IFRS 2 Charge for fair value of share options

2. Gains and losses recognised on cash flow hedges

3. Portion of deferred tax asset arising on outstanding share options and share options exercised

and not taken to profit and loss in accordance with IAS12.

Abcam plc

Notes to the consolidated financial information

For the year ended 30 June 2008

30. Explanation of the transition to IFRS

This is the first year that the company has presented its financial information under IFRS. The 

following disclosures are required in the year of transition. The last financial statements under

UK GAAP were for the year ended 30 June 2007 and the date of transition to IFRS was therefore

1 July 2006.

The principal impact of IFRS on this interim financial information has been in relation to 

the following:

a. The scope of IAS 32 and IAS 39, Financial Instruments: Presentation 

and Financial Instruments: Recognition and measurement respectively.

 IAS 32 and IAS 39 require the company to recognise derivative financial instruments at their fair 

value on the balance sheet (under UK GAAP, these were off balance sheet items).There may also

be a corresponding hedging reserve within equity on the balance sheet if hedge accounting

is applied.

The Group designates foreign exchange contracts as cash flow hedges and has implemented

hedge accounting.

b. The scope of IAS 12: Income taxes

Under IAS 12, a deferred tax asset arises on the unexercised share options issued to employees. 

Under UK GAAP the tax charge is only recognised in the income statement when the tax becomes 

payable.

Reconciliation of income statement for the year ended 30 June 2007

Group

UK GAAP

IFRS adjustment

IFRS

£000's

£000's

£000's

Revenue

24,519 

24,519 

Cost of Sales

(10,020)

(10,020)

 

 

 

Gross Profit

14,499 

14,499 

Administration and management expenses

a

(7,422)

(168)

(7,590)

 excluding share based compensation charge

 

Share based compensation charge

(142)

 

(142)

Total management and administration expenses

(7,564)

(168)

(7,732)

Research and Development expenses

(1,709)

(1,709)

 excluding share based compensation charge

 

 

Share based compensation charge

(20)

(20)

Total research and development expenses

(1,729)

(1,729)

 

 

 

OPERATING PROFIT

5,206 

(168)

5,038 

Investment revenue

495 

495 

 

 

 

PROFIT BEFORE TAXATION 

5,701 

(168)

5,533 

Tax 

b

(1,554)

82 

(1,472)

 

 

 

PROFIT FOR THE PERIOD FROM CONTINUING 

4,147 

(86)

4,061 

 OPERATIONS

Reconciliation of equity as at 1 July 2006 and 30 June 2007

1 July 2006

30 June 2007

Total Equity under UK GAAP

15,067

18,427

Loss/gains arising on derivatives

a

118

204 

in a designated cash flow hedge

Loss/gains arising on deferred 

b

290

256 

tax on outstanding options

Total Equity under IFRS

15,475

18,887

Reconciliation of balance sheet presentation at 1 July 2006

Group

UK GAAP

IFRS adjustment

IFRS

£000's

£000's

£000's

NON-CURRENT ASSETS

Intangible assets

77 

77 

Property, plant and equipment

1,094 

1,094 

1,171 

1,171 

CURRENT ASSETS

Inventories

2,358 

2,358 

Trade and other receivables

2,762 

2,762 

Cash and cash equivalents 

11,884 

11,884 

Derivative financial instruments

a

169 

169 

17,004 

169 

17,173 

CURRENT LIABILITIES

Trade and other payables

(2,461)

(2,461)

Current tax liabilities

a

(562)

(51)

(613)

(3,023)

(51)

(3,074)

NET CURRENT ASSETS

13,981 

118 

14,099 

TOTAL ASSETS LESS CURRENT LIABILITIES

15,152 

118 

15,270 

NON-CURRENT LIABILITIES

Deferred tax liabilities

b

(85)

290 

205 

NET ASSETS

15,067 

408 

15,475 

EQUITY

Share capital

345 

345 

Share premium account

10,573 

10,573 

Translation reserve

89 

89 

Share based compensation reserve

(8)

(8)

Retained earnings

a,b

4,068 

408 

4,476 

TOTAL EQUITY

15,067 

408 

15,475 

Reconciliation of balance sheet presentation at 1 July 2006

Company

UK GAAP

IFRS adjustment

IFRS

£000's

£000's

£000's

NON-CURRENT ASSETS

Intangible assets

77 

77 

Property, plant and equipment

901 

901 

Investments

16 

16 

994 

994 

CURRENT ASSETS

Inventories

2,348 

2,348 

Trade and other receivables

2,676 

2,676 

Cash and cash equivalents 

11,312 

11,312 

Derivative financial instruments

a

169 

169 

16,336 

169 

16,505 

CURRENT LIABILITIES

Trade and other payables

(2,294)

(2,294)

Current tax liabilities

a

(411)

(51)

(462)

(2,705)

(51)

(2,756)

NET CURRENT ASSETS

13,631 

118 

13,749 

TOTAL ASSETS LESS CURRENT LIABILITIES

14,625 

118 

14,743 

NON-CURRENT LIABILITIES

Deferred tax liabilities

b

(77)

290 

213 

NET ASSETS

14,548 

408 

14,956 

EQUITY

Share capital

345 

345 

Share premium account

10,573 

10,573 

Share based compensation reserve

89 

89 

Retained earnings

a,b

3,541 

408 

3,949 

TOTAL EQUITY

14,548 

408 

14,956 

Reconciliation of balance sheet presentation at 30 June 2007

Group

UK GAAP

IFRS adjustment

IFRS

£000's

£000's

£000's

NON-CURRENT ASSETS

Intangible assets

1,691 

1,691 

Property, plant and equipment

2,832 

2,832 

4,523 

4,523 

CURRENT ASSETS

Inventories

3,102 

3,102 

Trade and other receivables

4,327 

4,327 

Cash and cash equivalents 

a

10,709 

10,709 

Derivative financial instruments

168 

168 

18,138 

168 

18,306 

CURRENT LIABILITIES

Trade and other payables

(3,404)

36 

(3,368)

(3,404)

36 

(3,368)

NET CURRENT ASSETS

14,734 

204 

14,938 

TOTAL ASSETS LESS CURRENT LIABILITIES

19,257 

204 

19,461 

NON-CURRENT LIABILITIES

Deferred creditor

(386)

(386)

Deferred tax liabilities

b

(444)

256 

(188)

NET ASSETS

18,427 

460 

18,887 

EQUITY

Share capital

346 

346 

Share premium account

10,619 

10,619 

Translation reserve

(36)

(36)

Share based compensation reserve

251 

251 

Deferred tax reserve

b

256 

256 

Hedging reserve

a

168 

168 

Retained earnings

a

7,247 

36 

7,283 

TOTAL EQUITY

18,427 

460 

18,887 

Reconciliation of balance sheet presentation at 30 June 2007

Company

UK GAAP

IFRS adjustment

IFRS

£000's

£000's

£000's

NON-CURRENT ASSETS

Intangible assets

1,691 

1,691 

Property, plant and equipment

2,459 

2,459 

Investments

16 

16 

4,166 

4,166 

CURRENT ASSETS

Inventories

3,089 

3,089 

Trade and other receivables

4,572 

4,572 

Cash and cash equivalents 

10,055 

10,055 

Derivative financial instruments

a

168 

168 

17,716 

168 

17,884 

CURRENT LIABILITIES

Trade and other payables

(2,939)

(2,939)

Current tax liabilities

a

(279)

36 

(243)

(3,218)

36 

(3,182)

NET CURRENT ASSETS

14,498 

204 

14,702 

TOTAL ASSETS LESS CURRENT LIABILITIES

18,664 

204 

18,868 

NON-CURRENT LIABILITIES

Deferred creditor

(188)

(188)

Deferred tax liabilities

b

(642)

256 

(386)

NET ASSETS

17,834 

460 

18,294 

EQUITY

Share capital

346 

346 

Share premium account

10,619 

10,619 

Share based compensation reserve

251 

251 

Deferred tax reserve

b

256 

256 

Hedging reserve

a

168 

168 

Retained earnings

a

6,618 

36 

6,654 

TOTAL EQUITY

17,834 

460 

18,294 

Explanation of material adjustments to the cash flow statement for 2007

Cash held under on short term deposits is included in cash and cash equivalents under IFRS.

Under previous GAAP, these amounts were excluded from the cash flow statement.

There are no other material differences between the cash flow statement statement

presented under IFRS and the cash flow statement presented under previous GAAP.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR UUUAGBUPRPGR
Date   Source Headline
14th Dec 20227:00 amRNSCancellation - Abcam Plc
12th Dec 20228:00 amRNSUpdate on AIM Delisting
9th Dec 20225:30 pmRNSAbcam
8th Dec 20222:36 pmRNSHolding(s) in Company
30th Nov 20228:55 amRNSTotal Voting Rights
28th Nov 20222:21 pmRNSDirector/PDMR Shareholding - Correction
28th Nov 20222:21 pmRNSDirector/PDMR Shareholding - Correction
17th Nov 20223:59 pmRNSDirector/PDMR Shareholding
17th Nov 20223:57 pmRNSDirector/PDMR Shareholding
11th Nov 20223:30 pmRNSResult of General Meeting
31st Oct 20223:22 pmRNSTotal Voting Rights
17th Oct 20227:00 amRNSPropose cancellation of AIM shares notice of GM
17th Oct 20227:00 amRNSProposed cancellation of AIM shares & notice of GM
10th Oct 20224:45 pmRNSDirector/PDMR Shareholding
10th Oct 20222:01 pmRNSDirector/PDMR Shareholding
10th Oct 20221:59 pmRNSDirector/PDMR Shareholding
30th Sep 20223:50 pmRNSBlock Listing Six Monthly Return
30th Sep 20223:48 pmRNSTotal Voting Rights
12th Sep 202212:00 pmRNSInterim results for the period ended 30 June 2022
12th Sep 20227:00 amRNSAppointment of Non-Executive Director
1st Sep 20222:02 pmRNSAbcam attend Morgan Stanley Healthcare Conference
31st Aug 202211:16 amRNSTotal Voting Rights
17th Aug 20228:30 amRNSNotice of Results
29th Jul 202211:09 amRNSTotal Voting Rights
20th Jul 202212:00 pmRNSTrading Statement
4th Jul 20228:36 amRNSTotal Voting Rights
31st May 20224:22 pmRNSTotal Voting Rights
18th May 20224:30 pmRNSResult of AGM
3rd May 202212:41 pmRNSDirector/PDMR Shareholding
29th Apr 20224:01 pmRNSTotal Voting Rights
5th Apr 20224:35 pmRNSDirector/PDMR Shareholding
4th Apr 20227:00 amRNSPublication of 2021 ARA and Notice of AGM
31st Mar 202210:58 amRNSTotal Voting Rights
30th Mar 20222:41 pmRNSBlock listing Interim Review
28th Mar 20223:09 pmRNSBlock Listing application of Ordinary Shares
17th Mar 20221:18 pmRNSDirector/PDMR Shareholding Notification
14th Mar 202212:00 pmRNSResults for the period ended 31 December 2021
2nd Mar 20227:00 amRNSTotal Voting Rights
28th Feb 20227:00 amRNSNotice of Full Year Results
4th Feb 202212:02 pmRNSDirector/PDMR Shareholding
31st Jan 202211:49 amRNSTotal Voting Rights
27th Jan 202212:00 pmRNSTrading Statement
31st Dec 202112:49 pmRNSTotal Voting Rights
2nd Dec 20217:00 amRNSUpdate on 2021 General Meeting Resolution Vote
30th Nov 20213:25 pmRNSTotal Voting Rights
12th Nov 20215:28 pmRNSIssue of Equity and Replacement PDMR Notification
12th Nov 20214:17 pmRNSTotal Voting Rights
12th Nov 202112:34 pmRNSIssue of Equity and Replacement PDMR Notification
10th Nov 20214:56 pmRNSIssue of Equity and PDMR Notification
5th Nov 20213:19 pmRNSVesting of All Employee Share Scheme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.